Form4insider filings, from the source

SEC Form 4 · accession 0001209191-15-064104

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Aug 3, 2015
Accepted (ET)
Aug 5, 2015 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common stockF2Aug 3, 2015M701$0.3025A232,973ISee footnote
Common stockF2Aug 3, 2015M7,299$31.64A240,272ISee footnote
Common stockF4,F2Aug 3, 2015S8,000$110.60D232,272ISee footnote
Common stockF5holding———79,082ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)F6$0.3025Aug 3, 2015M701D—Aug 12, 2019Common stock701878,619D
Stock option (right to buy)F7$31.64Aug 3, 2015M7,299D—Mar 4, 2024Common stock7,299871,320D

Explanation of responses